We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Drugmakers need to better connect their clinical and R&D operations to cope with the growing cost and complexity of clinical trials amidst declining drug approvals. Read More
Dr. Reddy’s Laboratories has adopted a unique strategy to bypass legal issues surrounding its generic version of Nexium: changing the color of its capsules. Read More
Physician groups frustrated with federal plans to pair different biosimilar drugs together for billing and reimbursement purposes are turning to Congress for help. Read More
In anticipation of proposed guidance on biosimilar interchangeability, AbbVie is requesting that the FDA hold a hearing to ensure the agency considers all viewpoints. Read More
A law firm that represents drugmakers is urging the FDA to rethink its stance on granting meetings with senior agency officials, saying the existing policy can imperil drug research. Read More